Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells

Inclusion Criteria: * patients with primary refractory or relapsed disease (including relapse after previous SCT and active disease) * AML in complete remission of refractory * MDS RAEB-t/secondary AML * ALL * CML * Non-Hodgkin Lymphoma / Hodgkin Lymphoma * non malignant diseases (aplastic anemia, thalassemia, SCID) * relapsed Neuroblastoma * relapsed soft tissue sarcoma (Rhabdomyosarcoma, Ewing sarcoma, PNET * soft tissue sarcoma with primary bone metastases or bone marrow * in whom no matched donor was available, Exclusion Criteria: * \< 6 months after previous HSCT * active cerebral seizure conditions * massive progression of leukemias or solid tumours before planned trp. * left ventricular ejection fraction \<25% * creatinine clearance \<40ml/min before conditioning * respiratory insufficiency with oxygen demand or DLCO \<30% * Bilirubin \>4mg/dl, GOT/GPT \>400 * severe infection (HIV, Aspergillosis) * pregnancy